Impact of Tadalafil Once Daily in Men With Erectile Dysfunction—Including a Report of the Partners' Evaluation
Received 21 July 2009; accepted 14 November 2009. published online 08 March 2010.
Objectives
To evaluate the effect of tadalafil 5 mg taken once daily on efficacy (erection achievement and penetration) and overall sexual satisfaction in men with erectile dysfunction (ED) and their female partners.
Methods
This retrospective analysis included data pooled from 2 multicenter, randomized, double-blind, placebo-controlled trials that included 505 couples (tadalafil, n = 373; placebo, n = 132) in which the men received tadalafil 5 mg once daily or placebo for 12 weeks. Individual Sexual Encounter Profile (SEP) diaries were completed independently by the male subject and his female partner after each sexual intercourse attempt. The mean per-subject/per-partner percentage of “yes” responses to SEP diary questions were assessed, as was agreement between subjects' and partners' responses.
Results
Subjects and partners in the tadalafil-treated group reported significantly greater improvements in the man's ability to achieve some erection, vaginal penetration, and overall sexual satisfaction compared with the placebo-treated group (P < .001). For all intercourse attempts, the mean per-couple percentage of agreement for those in the tadalafil and placebo groups, respectively, was high for erection achievement (99.0% and 96.6%), vaginal penetration (98.6% and 97.4%), and overall satisfaction (84.3% and 82.8%).
Conclusions
Tadalafil 5 mg taken once daily as treatment for ED improved overall satisfaction for men and their female partners. This analysis demonstrates the high concordance among couples in their responses to the man's treatment for ED.
aCenter for Marital and Sexual Health of South Florida, West Palm Beach, Florida
bAsociación Mexicana para la Salud Sexual, Tlalpan, Brasília, Mexico
cCase Western Reserve University School of Medicine, Cleveland, Ohio
Reprint requests: Stanley E. Althof, Ph.D., Center for Marital and Sexual Health of South Florida, 1515 North Flagler Drive, Suite 540, West Palm Beach, FL 33401
This work was supported by Lilly, United States, LLC, including assistance with manuscript preparation provided by Danette Hann, PhD (i3 Statprobe).
Dr. Althof is consultant or adviser for Pfizer, Palitan, GSK, Eli Lilly, Boehringer-Ingelheim, Johnson and Johnson, Plethora and a Principal Investigator for Boehringer-Ingelheim and Plethora.
Dr. Rubio-Aurioles is currently a consultant, investigator and speaker for Eli Lilly, Bayer Schering, Boehringer-Ingelheim, and More Pharma, Mexico.
Dr. Kingsberg is an investigator for BioSante, Procter & Gamble, Boehringer-Ingelheim, a consultant for Wyeth and Boehringer-Ingelheim, on the speakers bureau for Eli Lilly, and has received honoraria from Johnson & Johnson.
Mrs. Zeigler is an employee of Lilly USA, LLC.
Dr. Wong and Dr. Burns are employees of Lilly, United States, LLC and own stock in the company.
ABSTRACT